Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

Interleukin Genetics Raises $10 Million in Financings

Business Wire December 23, 2014

Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa

GlobeNewswire December 23, 2014

Alcyone Lifesciences Appoints Michael Rogawski, International Expert in Treatment of Seizures and Epilepsy to its Clinical and Scientific Advisory Board

Business Wire December 23, 2014

Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics

PR Newswire December 23, 2014

Public Health Agency of Canada appoints new Scientific Director General of the National Microbiology Laboratory and Laboratory of Foodborne Zoonoses

Canada NewsWire December 23, 2014

Lieber Institute for Brain Development Publication Chosen for The American Journal of Psychiatry Year in Review

PR Newswire December 23, 2014

Stuart Williams, Ph.D. to Be Featured With BioAssemblyBot/TSIM Innovation on CNN's Moonshots for the 21st Century

Marketwired December 23, 2014

Personalised Healthcare: Panacea or Pandora's Box?

PR Newswire December 23, 2014

SeeThruEquity Initiates Research Coverage on Applied DNA Sciences, Inc. with a Price Target of $5.40

Accesswire December 23, 2014

Chimerix Provides Recap of 2014 Events

GlobeNewswire December 23, 2014

FDA Approves Teva's GRANIX® (tbo-filgrastim) Injection for Self-Administration

Business Wire December 23, 2014

Mirati Therapeutics Doses First Patient in Expansion Cohorts of Phase 1b Trial of MGCD265 in Genetically Selected Patients

PR Newswire December 23, 2014

PTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular Dystrophy

PR Newswire December 23, 2014

Cytokinetics and Astellas Announce Expansion of Collaboration for Development of CK-2127107 in Spinal Muscular Atrophy and Other Neuromuscular Indications

Thomson Reuters ONE December 23, 2014

ETST Wholly Owned Subsidiary "Nutrition Empire" Opens Its First Retail Health & Wellness Store in Coral Gables, FL Last Week, Starts Generating Revenue Selling Leading Nutritional and Dietary Supplements and ETST High Grade CBD (Cannabidiol) Rich Hemp Oil

Marketwired December 23, 2014

Christmas Gift to People Worldwide Suffering From "Flesh Eating" Disease: NovaBay Pharmaceuticals and the National Necrotizing Fasciitis Foundation Will Offer New Life- and Limb-Saving Treatment At No Charge to Patients Worldwide

Accesswire December 23, 2014

Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the Field of Immuno-oncology

Business Wire December 23, 2014

ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat Leukemias in Japan and Nine Other Asian Countries

Business Wire December 23, 2014

Theralase Reports Results of PDC Therapy of Bladder Cancer in Orthotopic Rat Model

TheNewsWire December 23, 2014

EB Pharma Announces License Agreement for Investigational Drug, Tipifarnib from Janssen Pharmaceutica for Development in Hepatitis Delta (HDV)

PR Newswire December 23, 2014